Top

Published in:

21-06-2023 | Review Article

Real-World Evidence Studies in Oncology Therapeutics: Hope or Hype?

Author: Sayanta Thakur

Published in: Indian Journal of Surgical Oncology | Issue 4/2023

Abstract

Randomized controlled trial (RCT) remains a gold standard in evidence-based medicine for assessing the efficacy and safety of cancer therapies. However, due to some inherent methodological limitations of RCT, such as stringent inclusion criteria, highly specific treatment, ethical and scientific compromise in rare cancer, and inability to adequately assess safety, real-world evidence (RWE) has been adjudged as a suitable option to complement data obtained from RCT. Moreover, in the context of cancer therapeutics, few notable merits pertain to developing a novel product for rare cancer subtypes, establishing new indications for already approved drugs, optimization of treatment regimen and sequence, a better description of long-term safety, and supporting the reimbursement-related decision. However, the implementation of RWE for the aforementioned purposes will be limited by various challenges, especially in the context of developing economies such as India. Special attention should be given to the availability of data, maintaining the quality standard, and establishing stringent regulations for privacy and security along with active regulatory engagement with relevant stakeholders. Such activities will be key to facilitating the use of RWE in cancer therapeutics.

Spieth PM, Kubasch AS, Isabel Penzlin A, Min-Woo Illigens B, Barlinn K, Siepmann T et al (2016) Randomized clinical trials - a matter of design. Neuropsychiatr Dis Treat 12:1341–1349PubMedPubMedCentral

The 21^st Century Cures Act. Public Law 114–255. 2016. Available from: https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf. Accessed 15 Sep 2022

Framework for FDA’s Real-World Evidence Program (2018) US Food and Drug Administration. Available from: https://www.fda.gov/media/120060/download. Accessed 15 Sep 2022

Spitzer E, Cannon CP, Serruys PW (2018) Should real-world evidence be incorporated into regulatory approvals? Expert Opin Drug Saf 17:1155–1159PubMed

Feinberg BA, Gajra A, Zettler ME, Phillips TD, Phillips EG, Kish JK (2020) Use of real-world evidence to support FDA approval of oncology drugs. Value Heal 23:1358–1365

Visvanathan K, Levit LA, Raghavan D, Hudis CA, Wong S, Dueck A et al (2017) Untapped potential of observational research to inform clinical decision making: American Society of Clinical Oncology Research statement. J Clin Oncol 35:1845–1854PubMed

Bolislis WR, Fay M, Kühler TC (2020) Use of real-world data for new drug applications and line extensions. Clin Ther 42:926–938PubMed

Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA (2020) Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf 29:1201–1212PubMed

Petracci F, Ghai C, Pangilinan A, Suarez LA, Uehara R, Ghosn M (2021) Use of real-world evidence for oncology clinical decision making in emerging economies. Futur Oncol 17:2951–2960

10.

Balen MC, Portier ESH, Fiocco M, Hartgrink HH, Langers AMJ, Neelis KJ et al (2022) Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer : clinical outcomes with the ‘CROSS-regimen’ in daily practice. Dis Esophagus 35:doab068

11.

Velcheti V, Hu X, Piperdi B, Burke T (2021) Real - world outcomes of first - line pembrolizumab plus pemetrexed - carboplatin for metastatic nonsquamous NSCLC at US oncology practices. Sci Rep 11:9222PubMedPubMedCentral

12.

Cramer-van der Welle CM, Verschueren MV, Tonn M, Peters BJM, Schramel FMNH, Klungel OH et al Santeon NSCLC Study Group (2021) Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Sci Rep 11:6306

13.

Tannock IF, Amir E, Booth CM, Niraula S, Ocana A, Seruga B et al (2016) Relevance of randomised controlled trials in oncology. Lancet Oncol 17:e560–e567PubMed

14.

Kostos L, Hong W, Lee B, Tran B, Lok SW, Anton A et al (2021) Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting. Int J Cancer 149:409–419PubMed

15.

Schilsky RL (2017) Finding the evidence in real-world evidence: moving from data to information to knowledge. J Am Coll Surg 224:1–7PubMed

16.

Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W (2015) Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in United States, 1990 to 2010. JAMA Oncol 1:88–96PubMedPubMedCentral

17.

Jin S, Pazdur R, Sridhara R (2017) Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. J Clin Oncol 35:3745–3752PubMedPubMedCentral

18.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al SHARP investigators study group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

19.

Sanoff HK, Chang Y, Lund JL, O’Neil BH, Dusetzina SB (2016) Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 21:1113–1120PubMedPubMedCentral

20.

Liu R, Rizzo S, Whipple S, Pal N, Pineda AL, Lu M et al (2021) Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature 592:629–633PubMedPubMedCentral

21.

Miller KL, Fermaglich LJ, Maynard J (2021) Using four decades of FDA orphan drug designations to describe trends in rare disease drug development : substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric - onset diseases. Orphanet J Rare Dis 16:265PubMedPubMedCentral

22.

Hilal T, Sonbol MB, Prasad V (2019) Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration. JAMA Oncol 5:887–892PubMedPubMedCentral

23.

Multi-Discipline Review (2017) Application Number: 761049Orig1s000. Center for Drug Evaluation and Research. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761049Orig1s000MultidisciplineR.pdf. Accessed 15 Sep 2022

24.

BLINCYTO ® (blinatumomab) for Minimal residual disease positive (MRD+) B-cell precursor acute lymphoblastic leukemia (ALL) (2018) Oncologic Drugs Advisory Committee, Amgen Inc. Available from: https://www.fda.gov/media/112191/download. Accessed 15 Sep 2022

25.

Medical Review(s) (2016) Application Number 125557Orig1s005. Center for Drug Evaluation and Research. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125557Orig1s005MedRedt.pdf. Accessed 15 Sep 2022

26.

Approval Package for Application Number 207103Orig1s008 (2019) Center for Drug Evaluation and Research. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/207103Orig1s008.pdf. Accessed 16 Sep 2022

27.

Kennedy-martin T, Curtis S, Faries D, Robinson S, Johnston J (2015) A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 16:495PubMedPubMedCentral

28.

Di Maio M, Perrone F, Conte P (2020) Real-world evidence in oncology: opportunities and limitations. Oncologist 25(5):e746-52PubMed

29.

Qureshi ZP, Vazquez ES, Monguio RR, Stevenson KB, Szeinbach SL (2011) Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf 20(7):772–777PubMed

30.

Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579–1589PubMedPubMedCentral

31.

de Moraes Hungria VT, Martínez-Baños DM, Peñafiel CR, Miguel CE, Vela-Ojeda J, Remaggi G et al (2020) Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology ( HOLA ) Observational Study, 2008–2016. Br J Haematol 188:383–393PubMed

32.

Subbiah V, Kurzrock R (2018) Challenging standard-of-care paradigms in the precision oncology era. Trends Cancer 4:101–109PubMedPubMedCentral

33.

Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F et al (2020) Enhancing global access to cancer medicines. CA Cancer J Clin 70:105–124PubMed

34.

Azoulay L (2022) Rationale, strengths, and limitations of real-world evidence in oncology : a canadian review and perspective. Oncologist 27:e731–e738PubMedPubMedCentral

35.

Luke JJ, Ghate SR, Kish J, Lee CH, Mcallister L, Mehta S et al (2019) Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma : a real-world study. Future Oncol 15:2933–2942PubMed

36.

Tan HS, Li H, Hong YW, Toh C, Wong A, Lopes G et al (2015) Efficacy and safety of an attenuated-dose sunitinib regimen in metastatic renal cell carcinoma : results from a prospective registry in Singapore. Clin Genitourin Cancer 13:e285–e295PubMed

37.

Cherla A, Renwick M, Jha A, Mossialos E (2020) EClinical medicine cost-effectiveness of cancer drugs : comparative analysis of the United States and England. EClinicalMedicine 29–30:100625PubMedPubMedCentral

38.

Al-Ziftawi NH, Shafie AA, Mohamed Ibrahim MI (2021) Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review. Expert Rev Pharmacoecon Outcomes Res 21:655–666PubMed

39.

Suvarna V (2010) Phase IV of drug development. Perspect Clin Res 1:57–60PubMedPubMedCentral

40.

Mofid S, Bolislis WR, Kühler TC (2022) Real-world data in the postapproval setting as applied by the EMA and the US FDA. Clin Ther 44:306–322PubMed

41.

A framework for regulatory use of real-world evidence (2017) Duke Margolis Center for Health Policy . Available from: https://healthpolicy.duke.edu/sites/default/files/2020-08/rwe_white_paper_2017.09.06.pdf Accessed 16 May 2023

42.

Real world data and evidence (2022) the future of indian clinical trials. Analytics Insight. Available from: https://www.analyticsinsight.net/real-world-data-and-evidence-the-future-of-indian-clinical-trials/. Accessed 18 Sep 2022

43.

Justo N, Espinoza MA, Ratto B, Nicholson M, Rosselli D, Ovcinnikova O et al (2019) Real-world evidence in healthcare decision making: global trends and case studies from Latin America. Value Heal 22:739–749

44.

Graham S, McDonald L, Wasiak R, Lees M, Ramagopalan S (2018) Time to really share real-world data? F1000Res 7:1054PubMedPubMedCentral

45.

India’s Data Integrity Problems (2015) Regulatory Affairs Personal Society. Available from: https://www.raps.org/regulatory-focus%E2%84%A2/news-articles/2015/2/india-s-data-integrity-problems. Accessed 18 Sep 2022

46.

Naidoo P, Bouharati C, Rambiritch V, Jose N, Karamchand S, Chilton R et al (2021) Real-world evidence and product development: opportunities, challenges and risk mitigation. Wien Klin Wochenschr 133:840–846PubMedPubMedCentral

47.

Tang M, Pearson SA, Simes RJ, Chua BH (2023) Harnessing real-world evidence to advance cancer research. Curr Oncol 30:1844–1859PubMedPubMedCentral

48.

Franklin JM, Schneeweiss S (2017) When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther 102:924–933PubMed

49.

Real-World Evidence Registry. ISPOR. Available from: https://www.ispor.org/strategic-initiatives/real-world-evidence/real-world-evidence-registry. Accessed 16 May 2023

50.

Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA et al (2021) STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ 372:m4856PubMedPubMedCentral

51.

Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I et al RECORD Working Committee (2015) The Reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med 12:e1001885

52.

Zhang J, Symons J, Agapow P, Teo JT, Paxton CA, Abdi J et al (2022) Best practices in the real-world data life cycle. PLOS Digit Health 1:e0000003PubMedPubMedCentral

53.

Miksad RA, Abernethy AP (2018) Harnessing the power of real-world evidence (RWE): a checklist to ensure regulatory-grade data quality. Clin Pharmacol Ther 103:202–205PubMed

54.

Hewer E (2020) The oncologist’s guide to synoptic reporting: a primer. Oncology 98:396–402PubMed

55.

McCoy LG, Banja JD, Ghassemi M, Celi LA (2020) Ensuring machine learning for healthcare works for all. BMJ Health Care Inform 27:e100237PubMedPubMedCentral

56.

Mitchell WG, Dee EC, Celi LA (2021) Generalisability through local validation: overcoming barriers due to data disparity in healthcare. BMC Ophthalmol 21:228PubMedPubMedCentral

57.

Sounderajah V, Clarke J, Yalamanchili S, Acharya A, Markar SR, Ashrafian H et al (2021) A national survey assessing public readiness for digital health strategies against COVID-19 within the United Kingdom. Sci Rep 11:5958PubMedPubMedCentral

Title: Real-World Evidence Studies in Oncology Therapeutics: Hope or Hype?
Author: Sayanta Thakur
Publication date: 21-06-2023
Publisher: Springer India
Published in: Indian Journal of Surgical Oncology / Issue 4/2023
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-023-01784-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Real-World Evidence Studies in Oncology Therapeutics: Hope or Hype?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

CT-Based Screening for Pulmonary Metastases in Head and Neck Squamous Cell Cancers: Diagnostic Accuracy and Cost Comparison with PET-CECT

A Comparison of Two Methods of Pre-operative Inspiratory Muscle Training on Post-operative Outcome Following Esophagectomy

Expression of Epidermal Growth Factor Receptor (EGFR) and β-catenin in Colorectal Carcinoma and its Correlation with Tumor Grade and Stage

Ki-67 Index and Its Correlation with Clinical and Pathological Variables in Breast Cancer

Standardised Critical Care Strategies Improve Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in an Indian Peritoneal Malignancy Centre

Role of Surgery in the Treatment of Abdominal Desmoid Fibromatosis: A Single-Center Experience